The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain

Clinical Epigenetics

Volumn 7, Issue 1, 2015, Pages

  Pangeni, Rajendra P ^a   Channathodiyil, Prasanna ^a   Huen, David S ^a   Eagles, Lawrence W ^a   Johal, Balraj K ^a   Pasha, Dawar ^a   Hadjistephanou, Natasa ^a   Nevell, Oliver ^a   Davies, Claire L ^a   Adewumi, Ayobami I ^a   Khanom, Hamida ^a   Samra, Ikroop S ^a   Buzatto, Vanessa C ^a   Chandrasekaran, Preethi ^a   Shinawi, Thoraia ^b   Dawson, Timothy P ^c   Ashton, Katherine M ^c   Davis, Charles ^c   Brodbelt, Andrew R ^d   Jenkinson, Michael D ^d   Bièche, Ivan ^e   Latif, Farida ^b   Darling, John L ^a   Warr, Tracy J ^a   Morris, Mark R ^a,b   more..

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ROYAL PRESTON HOSPITAL   (United Kingdom)

^d THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^e INSTITUT CURIE   (France)

Author keywords

Brain; Breast; DNA methylation; Epigenetic; Metastasis; Tumour suppressor

Indexed keywords

RNA;

ARTICLE; BNC1 GENE; BRAIN METASTASIS; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER STAGING; CCDC8 GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIGENETICS; GALNT9 GENE; GENE; GENETIC ANALYSIS; GENOME-WIDE ASSOCIATION STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHYLATION; PRIMARY TUMOR; PRIORITY JOURNAL; RNA INTERFERENCE;

EID: 84983085318     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-015-0089-x     Document Type: Article

References (103)

1. Gavrilovic IT, Posner JB. Brain metastases: Epidemiology and pathophysiology. J Neuro-Oncol. 2005;75(1):5-14.
2. Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249(10):1357-69.
3. Gori S et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: Incidence, survival, and risk factors. Oncologist. 2007;12(7):766-73.
4. Kennecke HF et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol. 2007;18(1):45-51.
5. Tosoni A, Franceschi E, Brandes AA. Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol. 2008;68(3):212-21.
6. Weil RJ et al. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005;167(4):913-20.
7. Soffietti R, Ruda R, Trevisan E. Brain metastases: Current management and new developments. Curr Opin Oncol. 2008;20(6):676-84.
8. Jenkinson MD et al. Management of cerebral metastasis: Evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer. 2011;47(5):649-55.
9. Sperduto PW et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-61.
10. SUGARBAKER ED. The organ selectivity of experimentally induced metastases in rats. Cancer. 1952;5(3):606-12.
11. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719-24.
12. TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
13. Curtis C et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-52.
14. Metzger FO, Ignatiadis M, Sotiriou C. Genomic Grade Index: an important tool for assessing breast cancer tumor grade and prognosis. Crit Rev Oncol Hematol. 2011;77(1):20-9.
15. Sanna G et al. Brain metastases in patients with advanced breast cancer. Anticancer Res. 2007;27(4C):2865-9.
16. van’t Veer LJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
17. Ryberg M et al. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat. 2005;91(3):217-25.
18. Zhang XH et al. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19(23):6389-97.
19. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834-46.
20. Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94. 696.
21. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8(5):329-40.
22. Klein CA. The systemic progression of human cancer: a focus on the individual disseminated cancer cell-the unit of selection. Adv Cancer Res. 2003;89:35-67.
23. Wang Y, Shang Y. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res. 2013;319(2):160-9.
24. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239-52.
25. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-93.
26. Park BK et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med. 2007;13(1):62-9.
27. Hill VK et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer. 2010;9:51.
28. Clark SJ et al. High sensitivity mapping of methylated cytocines. Nucleic Acid Research. 1994;22(15):2990-7.
29. Eichler AF et al. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344-56.
30. Patra SK, Bettuzzi S. Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2′-deoxycytidine and DNA-demethylation. Biochemistry (Mosc). 2009;74(6):613-9.
31. Morris MR et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29(14):2104-17.
32. Morris MR et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene. 2011;30(12):1390-401.
33. Mizuno H et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18.
34. Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics. 1982;38:1011-6.
35. Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.
36. Weigelt B, Peterse JL, van ‘t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591-602.
37. Cock-Rada A, Weitzman JB. The methylation landscape of tumour metastasis. Biol Cell. 2013;105(2):73-90.
38. Stephens PJ et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400-4.
39. Burstein HJ, Griggs JJ. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. J Clin Oncol. 2012;30(7):684-6.
40. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679-95.
41. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563-72.
42. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274-84.
43. Minn AJ et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518-24.
44. Kang Y et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537-49.
45. Safran M et al. GeneCards Version 3: the human gene integrator. Database. 2010. doi:10.1093/database/baq020.
46. Hanisch FG. O-glycosylation of the mucin type. Biol Chem. 2001;382(2):143-9.
47. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep. 2006;7(6):599-604.
48. Perey L, Hayes DF, Kufe D. Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res. 1992;52(22):6365-70.
49. Hayes DF et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol. 1991;9(7):1113-23.
50. van der Vegt B et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology. 2007;51(3):322-35.
51. de Roos MA et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure’ ductal carcinoma in situ of the breast. Histopathology. 2007;51(2):227-38.
52. Ghosh SK et al. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer. 2013;13(2):109-18.
53. Berois N et al. GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin Chem. 2013;59(1):225-33.
54. Raman J et al. UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases: completion of the family tree. Glycobiology. 2012;22(6):768-77.
55. Li X et al. Characterization of ppGalNAc-T18, a member of the vertebratespecific Y subfamily of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 2012;22(5):602-15.
56. Zhang Y et al. Cloning and characterization of a new human UDP-N-acetylalpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen. J Biol Chem. 2003;278(1):573-84.
57. Tuupanen S et al. Identification of 33 candidate oncogenes by screening for base-specific mutations. Br J Cancer. 2014;111(8):1657-62.
58. Brennan CW et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-77.
59. Research CGA. N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-50.
60. Research CGA, N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25.
61. Zhang S, Wang J, Tseng H. Basonuclin regulates a subset of ribosomal RNA genes in HaCaT cells. PLoS One. 2007;2(9), e902.
62. Wang J et al. Search for basonuclin target genes. Biochem Biophys Res Commun. 2006;348(4):1261-71.
63. Ma J et al. Basonuclin: a novel mammalian maternal-effect gene. Development. 2006;133(10):2053-62.
64. Shames DS et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006;3(12), e486.
65. Yi JM et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19(23):6544-55.
66. Devaney JM et al. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis. 2013;16(4):292-300.
67. Dunwell TL et al. Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics. 2009;4(3):185-93.
68. Feuerborn A et al. Basonuclin-1 modulates epithelial plasticity and TGF-beta1-induced loss of epithelial cell integrity. Oncogene. 2015;34(9):1185-95.
69. Guo L et al. Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar. Am J Pathol. 2011;178(5):2357-66.
70. Hanson D et al. Exome sequencing identifies CCDC8 mutations in 3-M syndrome, suggesting that CCDC8 contributes in a pathway with CUL7 and OBSL1 to control human growth. Am J Hum Genet. 2011;89(1):148-53.
71. Huber C et al. Identification of mutations in CUL7 in 3-M syndrome. Nat Genet. 2005;37(10):1119-24.
72. Huber C et al. A large-scale mutation search reveals genetic heterogeneity in 3M syndrome. EJHG. 2009;17(3):395-400.
73. Maksimova N et al. Clinical, molecular and histopathological features of short stature syndrome with novel CUL7 mutation in Yakuts: new population isolate in Asia. J Med Genet. 2007;44(12):772-8.
74. Huber C, Munnich A, Cormier-Daire V. The 3M syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25(1):143-51.
75. Yan J et al. The 3M complex maintains microtubule and genome integrity. Mol Cell. 2014;54(5):791-804.
76. Li Z et al. CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol Cell. 2014;54(5):805-19.
77. Tsukita S, Furuse M. The Structure and Function of Claudins, Cell Adhesion Molecules at Tight Junctions. Ann N Y Acad Sci. 2000;915:129-35.
78. Bragulla HH, Homberger DG. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia. J Anat. 2009;214(4):516-59.
79. Shimomura Y et al. Mutations in the keratin 85 (KRT85/hHb5) gene underlie pure hair and nail ectodermal dysplasia. J Invest Dermatol. 2010;130(3):892-5.
80. Magin TM, Vijayaraj P, Leube RE. Structural and regulatory functions of keratins. Exp Cell Res. 2007;313(10):2021-32.
81. Chen J et al. miR-127 regulates cell proliferation and senescence by targeting BCL6. PLoS One. 2013;8(11):e80266.
82. Luo H et al. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res. 2009;28:82.
83. Symmans WF. Tissue banking. Breast Cancer Res. 2010;12 Suppl 1:L1.
84. Chen Y et al. Retroviral delivery of homeobox D3 gene induces cerebral angiogenesis in mice. J Cereb Blood Flow Metab. 2004;24(11):1280-7.
85. Pellegrino L et al. miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res. 2013;41(10):5400-12.
86. Jin L et al. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer. Cancer Res. 2013;73(9):2884-96.
87. Majid S et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012;72(24):6435-46.
88. Zaman MS et al. Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One. 2012;7(11), e50203.
89. Kim YR et al. HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol Cancer. 2010;9:124.
90. Muggerud AA et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. BCR. 2010;12(1):R3.
91. Rosen H, Krichevsky A, Polakiewicz RD, Benzakine S, Bar-Shavit Z. Developmental regulation of proenkephalin gene expression in osteoblasts. Mol Endocrinol. 2013;9(11):1621-31.
92. Wagh PK, Peace BE, Waltz SE. Met‐Related Receptor Tyrosine Kinase Ron in Tumor Growth and Metastasis. Adv Cancer Res. 2008;100:1-33.
93. Sabine Strehl KG, Qiu ML, Heather G, Lalande M. Characterization of Two Novel Protocadherins (PCDH8 and PCDH9) Localized on Human Chromosome 13 and Mouse Chromosome 14. Genomics. 1998;53:81-9.
94. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998;12:2048-60.
95. Takeda K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Dev Biol. 1997;94:3801-4.
96. Akira S. Roles of STAT3 defined by tissue-specifc gene targeting. Oncogene. 2000;19(21):2607-11.
97. Osler ME, Smith TK, Bader DM. Bves, a member of the Popeye domain-containing gene family. Dev Dyn. 2006;235(3):586-93.
98. Hill VK et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011;71(8):2988-99.
99. Osanai M et al. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Sci. 2007;98(10):1557-62.
100. Carrio M et al. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res. 2005;65(16):7177-85.
101. Shinya Toba MT, Morichika KTM, et al. Brain-speci¢c expression of a novel human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T9). Biochim Biophys Acta. 2000;1493:264-8.
102. Ai L et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis. 2006;27(7):1341-8.
103. Veeck J et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer. 2009;9:217.